BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

Current stock price

24 EUR
-0.6 (-2.44%)
Last:

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • BLC had positive earnings in the past year.
  • In the past year BLC had a positive cash flow from operations.
  • BLC had positive earnings in 4 of the past 5 years.
  • In the past 5 years BLC always reported a positive cash flow from operatings.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • The Return On Assets of BLC (0.08%) is worse than 69.70% of its industry peers.
  • The Return On Equity of BLC (0.74%) is worse than 66.67% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 6.43%, BLC is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BLC is in line with the industry average of 6.44%.
  • The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROIC 6.43%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • BLC's Profit Margin of 0.11% is on the low side compared to the rest of the industry. BLC is outperformed by 69.70% of its industry peers.
  • In the last couple of years the Profit Margin of BLC has declined.
  • BLC's Operating Margin of 8.21% is in line compared to the rest of the industry. BLC outperforms 57.58% of its industry peers.
  • In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
  • With an excellent Gross Margin value of 67.80%, BLC belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BLC has grown nicely.
Industry RankSector Rank
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BLC.PA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BLC is still creating some value.
  • BLC has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
  • BLC has a better debt/assets ratio than last year.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.39, we must say that BLC is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.39, BLC is not doing good in the industry: 60.61% of the companies in the same industry are doing better.
  • BLC has a debt to FCF ratio of 12.90. This is a negative value and a sign of low solvency as BLC would need 12.90 years to pay back of all of its debts.
  • BLC has a Debt to FCF ratio of 12.90. This is in the lower half of the industry: BLC underperforms 66.67% of its industry peers.
  • BLC has a Debt/Equity ratio of 5.29. This is a high value indicating a heavy dependency on external financing.
  • BLC's Debt to Equity ratio of 5.29 is on the low side compared to the rest of the industry. BLC is outperformed by 84.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Altman-Z 1.39
ROIC/WACC1.22
WACC5.26%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • BLC has a Current Ratio of 1.38. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.38, BLC is doing good in the industry, outperforming 69.70% of the companies in the same industry.
  • A Quick Ratio of 1.18 indicates that BLC should not have too much problems paying its short term obligations.
  • BLC has a Quick ratio of 1.18. This is in the better half of the industry: BLC outperforms 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.18
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
  • Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
  • Looking at the last year, BLC shows a small growth in Revenue. The Revenue has grown by 6.35% in the last year.
  • The Revenue has been growing slightly by 5.12% on average over the past years.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%

3.2 Future

  • Based on estimates for the next years, BLC will show a small growth in Earnings Per Share. The EPS will grow by 5.90% on average per year.
  • The Revenue is expected to grow by 7.69% on average over the next years.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

4

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • BLC is valuated quite expensively with a Price/Earnings ratio of 342.86.
  • 75.76% of the companies in the same industry are cheaper than BLC, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of BLC to the average of the S&P500 Index (25.79), we can say BLC is valued expensively.
  • A Price/Forward Earnings ratio of 13.02 indicates a correct valuation of BLC.
  • BLC's Price/Forward Earnings is on the same level as the industry average.
  • BLC's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.80.
Industry RankSector Rank
PE 342.86
Fwd PE 13.02
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaper than 90.91% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BLC indicates a rather cheap valuation: BLC is cheaper than 81.82% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5.55
EV/EBITDA 5.62
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • BLC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (3/19/2026, 5:29:29 PM)

24

-0.6 (-2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners12.76%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap176.88M
Revenue(TTM)491.18M
Net Income(TTM)533.00K
Analysts77.14
Price Target36.21 (50.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP106.75%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.26%
EPS NY rev (3m)-26.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 342.86
Fwd PE 13.02
P/S 0.36
P/FCF 5.55
P/OCF 1.92
P/B 2.45
P/tB N/A
EV/EBITDA 5.62
EPS(TTM)0.07
EY0.29%
EPS(NY)1.84
Fwd EY7.68%
FCF(TTM)4.32
FCFY18.02%
OCF(TTM)12.48
OCFY51.99%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.93
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROCE 8.75%
ROIC 6.43%
ROICexc 6.81%
ROICexgc 12.17%
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
FCFM 6.49%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Debt/EBITDA 3.78
Cap/Depr 99.07%
Cap/Sales 12.23%
Interest Coverage 250
Cash Conversion 91.09%
Profit Quality 5980.3%
Current Ratio 1.38
Quick Ratio 1.18
Altman-Z 1.39
F-Score8
WACC5.26%
ROIC/WACC1.22
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y18.78%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.


What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?

The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to decline by -12.23% in the next year.


Can you provide the dividend sustainability for BLC stock?

The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 106.75%.